Anti‐ELTD1 and OKN treatments both normalized tumour vascular perfusion rates compared to untreated and bevacizumab (anti‐ELTD1: UT ****p < 0.0001, bevacizumab **p = 0.0061, OKN: UT ****p < 0.0001, bevacizumab **p = 0.0027). The gene discussed is ADGRL4; the disease is neoplasm.